Healthcare -
Biotechnology - NASDAQ - US
$ 1.71
-8.56 %
$ 386 M
Market Cap
-1.47
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Sana Biotechnology, Inc.
| Net Income | -267 M |
| Depreciation & Amortization | 17.4 M |
| Capital Expenditures | -33.4 M |
| Stock-Based Compensation | 37.7 M |
| Change in Working Capital | -1.18 M |
| Others | -12.8 M |
| Free Cash Flow | -257 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (266.8) | (283.3) | (269.5) | (355.9) | (285.3) | (130.8) | (13.2) |
| Depreciation & Amortization | 17.4 | 24.6 | 15.6 | 11.1 | 5.9 | 1.8 | 1 K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 | (7.5) | 0 |
| Stock Based Compensation | 37.7 | 35.5 | 38.3 | 22.4 | 5.8 | 1.5 | 0.1 |
| Other Operating Activities | (10.3) | (49.0) | (82.1) | 61.6 | 129.4 | 39.0 | (0.2) |
| Change in Working Capital | (1.2) | 18.6 | 7.5 | 9.8 | 6.2 | 10.5 | (0.3) |
| Cash From Operations | (223.2) | (253.6) | (290.1) | (251.1) | (138.0) | (85.5) | (13.5) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | (33.4) | (20.0) | (20.9) | (29.9) | (23.9) | (26.2) | (0.5) |
| Other Items | 50.9 | 192.0 | 231.4 | (215.9) | (228.7) | (61.7) | (0.3) |
| Cash From Investing Activities | 17.5 | 172.0 | 210.6 | (245.8) | (252.6) | (87.9) | (0.8) |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 7.7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.0 | 0 | 0 | 0 | 435.7 | 223.7 | 0 |
| Cash From Financing Activities | 199.7 | 31.6 | 4.9 | 631.8 | 435.7 | 223.7 | 45.7 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | (6.0) | (49.9) | (74.6) | 134.9 | 45.1 | 50.4 | 31.4 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (256.6) | (273.6) | (310.9) | (280.9) | (161.9) | (111.7) | (14.0) |